Ma JA - Search Results

1

Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.

Wan XM, Peng LB, Ma JA, Li YJ. Wan XM, et al. Among authors: ma ja. Cancer. 2017 Jul 15;123(14):2634-2641. doi: 10.1002/cncr.30666. Epub 2017 Mar 16. Cancer. 2017. PMID: 28301684 Free article.

2

Subgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy.

Wan X, Peng L, Ma J, Chen G, Li Y. Wan X, et al. Clin Ther. 2015 Nov 1;37(11):2515-2526.e5. doi: 10.1016/j.clinthera.2015.09.007. Epub 2015 Oct 21. Clin Ther. 2015. PMID: 26475419

3

Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.

Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L. Wan X, et al. Breast. 2019 Feb;43:1-6. doi: 10.1016/j.breast.2018.10.004. Epub 2018 Oct 16. Breast. 2019. PMID: 30342258

4

circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).

Tang YF, Liu ZH, Zhang LY, Shi SH, Xu S, Ma JA, Hu CH, Zou FW. Tang YF, et al. Among authors: ma ja. Mol Cancer. 2024 May 7;23(1):91. doi: 10.1186/s12943-024-01998-w. Mol Cancer. 2024. PMID: 38715012 Free PMC article.

5

[Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer].

Luo D, Ma J, Zhang J, Zhao Y. Luo D, et al. Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):415-420. doi: 10.3779/j.issn.1009-3419.2017.06.08. Zhongguo Fei Ai Za Zhi. 2017. PMID: 28641700 Free PMC article. Review. Chinese.

6

Synchronous colorectal cancer and multiple myeloma with chest wall involvement: Is this a coincidence?

Li QL, Ma JA, Li HP, Huang RB, Hu CH, Liu XL, Gao YW, Feng GH, Wu F. Li QL, et al. Among authors: ma ja. Curr Probl Cancer. 2017 Nov-Dec;41(6):413-418. doi: 10.1016/j.currproblcancer.2017.09.002. Epub 2017 Sep 25. Curr Probl Cancer. 2017. PMID: 29129340 Review.

7

Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel.

Guo L, Peng H, Cai HL, Tang D, Hu H, Wang F, Liu J, Que KL, Han C, Zhang Y, Yan M, Ma JA. Guo L, et al. Among authors: ma ja. Cancer Chemother Pharmacol. 2019 Apr;83(4):727-734. doi: 10.1007/s00280-019-03777-7. Epub 2019 Jan 24. Cancer Chemother Pharmacol. 2019. PMID: 30680523 Clinical Trial.

8

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.

Zhao X, Zhang N, Zhang H, Liu P, Ma J, Hu C, Liu X, Hou T. Zhao X, et al. Medicine (Baltimore). 2020 Nov 13;99(46):e23150. doi: 10.1097/MD.0000000000023150. Medicine (Baltimore). 2020. PMID: 33181687 Free PMC article.

9

Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs.

Jiang S, Wang S, Wang Q, Deng C, Feng Y, Ma F, Ma J, Liu X, Hu C, Hou T. Jiang S, et al. Cancer Manag Res. 2021 Feb 15;13:1315-1322. doi: 10.2147/CMAR.S287897. eCollection 2021. Cancer Manag Res. 2021. PMID: 33633464 Free PMC article.

10

A promising treatment option for refractory male primary choriocarcinoma: report of two cases.

Han C, Zhou Y, Ma JA, Liu J, Jiang YN, Zhang HX. Han C, et al. Among authors: ma ja. Transl Cancer Res. 2020 Apr;9(4):3054-3060. doi: 10.21037/tcr.2020.02.05. Transl Cancer Res. 2020. PMID: 35117666 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

190 results

Search Page

Filters